An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study

Trial Profile

An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 15 Mar 2017 This trial has been completed in Austria as per European Clinical Trials Database.
    • 01 Jul 2015 Planned End Date changed from 1 Jul 2019 to 1 May 2024 as reported by ClinicalTrials.gov record.
    • 01 Jul 2015 Planned primary completion date changed from 1 Jul 2019 to 1 May 2024 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top